Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Abstract

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

• Authors: Roy T Steigbigel, David A Cooper, Hedy Teppler, Joseph J Eron, Jose M Gatell, Princy N Kumar, Jurgen K Rockstroh, Mauro Schechter, Christine Katlama, Martin Markowitz, Patrick Yeni, Mona R Loutfy, Adriano Lazzarin, Jeffrey L Lennox, Bonaventura Clotet, Jing Zhao, Hong Wan, Rand R Rhodes, Kim M Strohmaier, Richard J Barnard, Robin D Isaacs, Bach-Yen T Nguyen, BENCHMRK Study Teamsa
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 50 Issue 4 Pg. 605-12 (Feb 15 2010) ISSN: 1537-6591 [Electronic] United States
• PMID: 20085491 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Pyrrolidinones
• RNA, Viral
• Raltegravir Potassium

Topics

• Anti-HIV Agents (adverse effects, therapeutic use)
• CD4 Lymphocyte Count
• Double-Blind Method
• Drug Resistance, Viral
• Drug Therapy, Combination
• Female
• HIV Infections (drug therapy)
• HIV-1 (drug effects)
• Humans
• Male
• Middle Aged
• Pyrrolidinones (adverse effects, therapeutic use)
• RNA, Viral (blood)
• Raltegravir Potassium
• Viral Load